Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Hodi, Frank Stephen, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Cowey, Charles Lance, Lao, Christopher D, Schadendorf, Dirk, Wagstaff, John, Dummer, Reinhard, FerrucLanguage:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(18)30700-9
Date:
October, 2018
File:
PDF, 1.31 MB
english, 2018